Previous Article | Next Article ![]()
Molecular and Cellular Biology, July 2001, p. 4208-4218, Vol. 21, No. 13
Department of Pharmacology, Rappaport Faculty
of Medicine, Technion-Israel Institute of Technology, Bat Galim, Haifa
31096, Israel,1 and Department of
Medicine, Department of Microbiology and Immunology, and Howard Hughes
Medical Institute, University of California, San Francisco, San
Francisco, California 94143-07952
Received 9 October 2000/Returned for modification 14 December
2000/Accepted 4 April 2001
SLP-76 is an adapter protein required for T-cell receptor (TCR)
signaling. In particular, TCR-induced tyrosine phosphorylation and
activation of phospholipase C- The role of adapter proteins in
signaling is increasingly appreciated (34). Adapters lack
catalytic activity but nucleate signaling complexes and mediate
intermolecular interactions, leading to increased speed and precision
of signaling. SLP-76 is a cell-type-specific adapter protein that is
expressed in T lymphocytes, NK cells, platelets, and myeloid cells of
the granulocyte and monocyte lineage (6, 24, 35, 43). In
these cell types, SLP-76 is required for signaling by ITAM
(immunoreceptor tyrosine-based activation motif)-containing receptors,
including the T-cell antigen receptor (TCR), the pre-TCR, the
high-affinity immunoglobulin E (IgE) receptor, and the platelet
collagen receptor (5, 7, 17, 36, 37, 64). In B cells, an
analogous adapter, BLNK/SLP-65, is required for signaling by the
ITAM-containing B-cell receptor (BCR) (16, 22, 58).
The primary structure of SLP-76 includes three domains capable of
mediating intermolecular interactions: an N-terminal acidic domain
containing three tyrosine phosphorylation sites, a central proline-rich
region, and a C-terminal Src homology 2 (SH2) domain (14,
24). Overexpression of SLP-76 augments TCR-induced
transcriptional responses (31, 54, 62) and affects
regulation of the actin cytoskeleton (55).
Interestingly, all three domains of SLP-76 are required for
augmentation of TCR-induced transcriptional responses by
overexpressed SLP-76 (14, 33, 54), suggesting that
multiple protein-protein interactions play a role in SLP-76 function.
Characterization of the SLP-76-deficient T-cell line J14 revealed that
SLP-76 is required to couple TCR-induced tyrosine kinase activity to
the tyrosine phosphorylation and activation of phospholipase C- PLC- Three families of tyrosine kinases are required for antigen
receptor-induced tyrosine phosphorylation and activation of PLC- Many different signaling proteins are known to interact with SLP-76;
however, their contribution to SLP-76-mediated activation of PLC- In this study, we take a genetic approach to identifying the
functionally essential domains of SLP-76 and the functionally important
SLP-76-interacting proteins, by identifying the regions of SLP-76 that
are required to reconstitute TCR signaling in a SLP-76-deficient T-cell
line. Our studies have identified a new functional domain within the
proline-rich region of SLP-76, comprised of amino acids 157 to 223, which associates with the SH3 domain of PLC- Plasmids.
The mutant alleles of SLP-76 used in this study
are depicted in Fig. 1B. All alleles were
Flag tagged at the N terminus and were subcloned as
SalI-XbaI fragments into pEFBos (30)
for use in transient transfections. The wild-type,
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.13.4208-4218.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of a Phospholipase C-
1 (PLC-
1)
SH3 Domain-Binding Site in SLP-76 Required for T-Cell Receptor-Mediated
Activation of PLC-
1 and NFAT
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
1 (PLC-
1), and the resultant TCR-inducible gene expression, depend on SLP-76. Nonetheless, the
mechanisms by which SLP-76 mediates PLC-
1 activation are not well
understood. We now demonstrate that SLP-76 directly interacts with the
Src homology 3 (SH3) domain of PLC-
1. Structure-function analysis of
SLP-76 revealed that each of the previously defined protein-protein
interaction domains can be individually deleted without completely
disrupting SLP-76 function. Additional deletion mutations revealed a
new, 67-amino-acid functional domain within the proline-rich region of
SLP-76, which we have termed the P-1 domain. The P-1 domain mediates a
constitutive interaction of SLP-76 with the SH3 domain of PLC-
1 and
is required for TCR-mediated activation of Erk, PLC-
1, and NFAT
(nuclear factor of activated T cells). The adjacent Gads-binding domain
of SLP-76, also within the proline-rich region, mediates inducible
recruitment of SLP-76 to a PLC-
1-containing complex via the
recruitment of both PLC-
1 and Gads to another cell-type-specific
adapter, LAT. Thus, TCR-induced activation of PLC-
1 entails the
binding of PLC-
1 to both LAT and SLP-76, a finding that may underlie
the requirement for both LAT and SLP-76 to mediate the optimal
activation of PLC-
1.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
1
(PLC-
1) (64). PLC-
1 catalyzes the formation of the
second messengers, inositol 1,4,5-trisphosphate (IP3) and
diacylglycerol, which, respectively, trigger calcium flux and
contribute to protein kinase C and Ras activation. In addition, PLC-
contributes to the activation of Erk (11, 18). These key
signaling events are required for activation of NFAT (nuclear factor of
activated T cells), a regulator of interleukin-2 transcription
(41, 60). Accordingly, in SLP-76-deficient J14 cells,
impaired PLC-
1 activation is associated with reduced TCR-induced
calcium flux and Erk activation and impaired TCR-induced
transcriptional responses (64).
1 activity is regulated by tyrosine phosphorylation (4,
42). All PLC family members contain two domains, designated X
and Y, which fold together to form the catalytic site. In the PLC-
subfamily (PLC-
1 and PLC-
2), the X and Y domains are separated by
two SH2 domains and one SH3 domain, bounded by a split pleckstrin homology domain (4, 42). Evidence suggests that this SH
region negatively regulates the basal activity of the PLC-
1
holoenzyme (19, 20). The tyrosine phosphorylation sites of
PLC-
1 have been identified as residues 771, 783, and 1254. Of these
sites, tyrosines 783 and 1254 are required for activation of PLC-
1
(25), although tyrosine kinase-independent mechanisms may
also contribute to PLC-
activation (48). Interestingly,
tyrosine 783 is located within the SH region, between the second SH2
and the SH3 domains.
1: a
Src family kinase, a Syk family kinase, and a Tec family kinase (reviewed in reference 4). In T cells, these kinases are
coupled to PLC-
1 activation by two cell-type-specific adapter
proteins: SLP-76, and a membrane-anchored, inducibly
tyrosine-phosphorylated adapter protein called LAT (15, 64, 66,
67). The Src family kinase is required for phosphorylation of
receptor ITAMs and contributes to the activation of the Syk and Tec
family kinases (38, 65). The Syk and Tec family kinases
may make a dual contribution to PLC-
activation, by phosphorylating
the SLP-76 and LAT adapter proteins and by phosphorylating PLC-
1
itself. Following TCR stimulation, the N-terminal SH2 domain of
PLC-
1 binds to tyrosine-phosphorylated LAT (50, 56,
67). Whereas LAT is required for tyrosine phosphorylation and
activation of PLC-
1 (15, 66), binding to LAT is not
sufficient for optimal tyrosine phosphorylation and activation of
PLC-
1 in the absence of SLP-76 (64). SLP-76 is
indirectly recruited to the LAT complex by the Grb2 family adapter
protein Gads, which binds to both SLP-76 and LAT (1, 29).
It is likely that SLP-76 acts as part of a complex with LAT to
influence tyrosine phosphorylation of PLC-
1.
1
has not been studied. Tyrosines 113 and 128 of SLP-76 mediate the
TCR-inducible association of SLP-76 with the Nck adapter protein
(55, 63) and with Vav, a hematopoietic cell-specific exchange factor for Rho family GTPases (13, 40, 53, 62). A
short stretch (amino acids 224 to 265) within the proline-rich domain
of SLP-76 was originally identified as a Grb2-binding site (31) but is now known to bind with higher affinity to Gads
(1, 29) (also known as Grb40, GrpL, GRID, Mona, and
Grap-2), a hematopoietically expressed, Grb2-related adapter protein
(1, 2, 12, 26, 29, 39). In addition, two tyrosine kinases
critical for TCR signaling, Lck and Itk, can associate via their SH3
domains with proline-rich motifs found in SLP-76 (3, 44),
while the SH2 domain of Itk has been further suggested to bind to
N-terminal tyrosine phosphorylation sites in SLP-76 (52).
Finally, the C-terminal SH2 domain of SLP-76 interacts with another
adapter protein, SLAP-130/Fyb (8, 32). The relative
functional importance of each of these interactions remains to be
sorted out.
1 and is required for
TCR-mediated activation of PLC-
1. We propose that binding of the SH3
domain of PLC-
1 to SLP-76 is required for optimal tyrosine
phosphorylation and activation of PLC-
1.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
N, Y3F,
Gads,
SH2, and SH2mut alleles of SLP-76 have been previously
described (14, 33) and were generously provided by Gary
Koretzky. Additional mutants were created, using standard PCR
techniques to precisely remove codons for the deleted residues,
indicated in Fig. 1. All PCR-generated constructs were verified by
sequencing. For stable transfections, SLP-76 alleles were subcloned
into the pAWneo3' expression vector, which bears a G418 resistance
selectable marker and allows for more physiologic expression levels.
The NFAT-luciferase reporter construct, in which the expression of
luciferase is driven by multiple copies of the NFAT DNA-binding
element, was a gift from G. Crabtree, Stanford University.

View larger version (21K):
[in a new window]
FIG. 1.
SLP-76 expression constructs used in this study. (A) The
major functional domains of SLP-76, as defined in references 14
and 33. (B) Diagrammatic depiction of the SLP-76 mutant
constructs used in this study. All constructs are Flag tagged at the N
terminus. Names of the constructs are shown at the left, and the
residues mutated or deleted are shown at the right.
GST fusion proteins.
Glutathione S-transferase
(GST) fusion proteins were expressed in bacteria and purified on
glutathione-agarose (Sigma) by standard procedures. A bacterial
expression construct encoding GST fused to the second SH3 domain of Nck
was provided by Bruce Mayer (University of Connecticut). The rat
PLC-
1 cDNA was generously provided by Graham Carpenter (Vanderbilt
University). Sequences encoding residues 538 to 851 (two SH2 and one
SH3 domains) and residues 790 to 851 (the SH3 domain) of rat PLC-
1
and were amplified by PCR and subcloned into pGEX2TK (Amersham
Pharmacia Biotech) to generate GST-PLC-
1 SH223 and GST-PLC-
1
SH3, respectively.
Cell culture and transfections. The SLP-76-deficient cell line J14 and its SLP-76-reconstituted derivative J14-76-11 have been previously described (64). Additional derivatives were obtained by stably transfecting J14 with mutant alleles of SLP-76 using the pAWneo3' expression vector. At least four clones expressing similar levels of surface TCR and transfected SLP-76 were chosen for analysis. All cells were maintained in RPMI 1640 medium supplemented with 5% fetal calf serum, penicillin, streptomycin, and glutamine. In addition, growth media for stably transfected derivatives of J14 contained G418 (2 mg/ml), of which was washed out 2 days prior to use of the cells for experiments. Transient transfections were performed by electroporation using a Gene Pulser (Bio-Rad Laboratories, Hercules, Calif.), at a setting of 250 V and 960 µF, in cuvettes containing 2 × 107 cells in 0.4 ml serum-free RPMI 1640 and the amount and type of DNA as indicated in the figure legends. Following transfection, cells were incubated for 20 h in RPMI 1640 containing 10% fetal calf serum and processed as indicated for each experiment.
Antibodies.
The monoclonal antibody C305 (specific for the
Jurkat Ti
chain) (57) was used for anti-TCR
stimulations. M2 (anti-Flag epitope) was obtained from Sigma.
Anti-PLC-
1 mixed monoclonal antibodies and antiphosphotyrosine
monoclonal antibody 4G10 were purchased from Upstate Biotechnology,
Inc. Polyclonal anti-PLC-
1 was purchased from Santa Cruz
Biotechnology. Polyclonal anti-Nck antiserum was provided by Joseph
Schlessinger (New York University). Sheep anti-human SLP-76 was
provided by Gary Koretzky (University of Pennsylvania).
Anti-phospho-ERK antibodies were purchased from New England Biolabs.
Polyclonal anti-Erk antiserum was obtained from Zymed. Anti-Gads was
obtained from C. Jane McGlade (University of Toronto).
Luciferase assays. Cells were transiently cotransfected with 20 µg of an NFAT luciferase reporter plasmid along with the plasmids indicated in figure legends; 20 to 24 h later, cells were aliquoted into a 96-well cell culture dish at 105 cells/well and stimulated for 6 h at 37°C with various stimuli. Cells were lysed and assayed for luciferase activity as previously described (61). To correct for variations in transfection efficiency, the NFAT luciferase activity obtained upon receptor stimulation was normalized to the activity obtained upon treatment with phorbol myristate acetate (PMA; 20 to 50 ng/ml) plus ionomycin (1 µM).
Immunoprecipitations and GST pull-downs.
Cells were washed
in phosphate-buffered saline containing Ca2+ and
Mg2+ (PBS), preheated to 37°C for 10 min, and either mock
stimulated with PBS or stimulated for various times with C305
(anti-TCR). Cells were then collected and lysed at 2 × 108 cells/ml in cold lysis buffer containing 1% Nonidet
P-40, 10 mM Tris (pH 7.6), and 150 mM NaCl supplemented with protease
and phosphatase inhibitors as described elsewhere (51), as
well as 50 mM NaF, 50 mM
-glycerol phosphate (pH 7.5), and 20 mM
sodium pyrophosphate (pH 7.5). After 15 min at 4°C, lysates were
centrifuged at 4°C in a microcentrifuge at 13,000 rpm for 10 min and
then in a Beckman Optima miniultracentrifuge at 100,000 × g for 11 min. Supernatants were collected and used for affinity
purification on antibody- or GST fusion protein-coated beads, as
described below.
| |
RESULTS |
|---|
|
|
|---|
Functional analysis of SLP-76 domain mutants on a SLP-76-null genetic background. Previous studies have defined three functional domains within SLP-76: an N-terminal acidic domain containing three tyrosine phosphorylation sites, a small segment of the proline-rich domain responsible for binding to Gads, and a C-terminal SH2 domain (Fig. 1A). Interestingly, all three domains are required for augmentation of TCR signaling by overexpressed SLP-76 (14, 33, 54). However, the cells used for overexpression studies express endogenous, wild-type SLP-76, which can provide compensatory function in trans. As a result, these studies could not address the structural requirements for the normal, physiologic function of SLP-76.
To address this question, we transiently transfected SLP-76-deficient T cells (J14) with different SLP-76 alleles, each containing an inactivating mutation in one of the three known SLP-76 domains (Fig. 1B, first four constructs). We measured TCR-induced activation of the NFAT transcription factor, using soluble anti-TCR as a stimulus (Fig. 2A). All SLP-76 alleles were expressed at levels similar to or higher than wild-type protein levels (Fig. 2C). As shown previously (64), vector-transfected J14 cells do not activate NFAT in response to TCR stimulation, while cells transfected with wild-type SLP-76 exhibit robust, TCR-induced NFAT activation. Compared to wild-type SLP-76, deletion or point mutation of the the N-terminal tyrosine phosphorylation sites or deletion of the Gads-binding domain significantly decreased SLP-76 function in response to soluble anti-TCR (Fig. 2A). Likewise, a point mutation inactivating the SH2 domain decreased SLP-76 function, though to a lesser degree. These results confirm, as suggested by previous studies (14, 31, 33, 54), that the N-terminal tyrosine phosphorylation sites, the Gads-binding domain, and the SH2 domain all contribute to SLP-76 function. Nonetheless, using immobilized anti-TCR to provide a stronger stimulus, we found that all of the mutants tested retained significant ability to reconstitute NFAT activation in J14 cells (Figure 2B). We conclude that whereas the three domains tested contribute to the optimal function of SLP-76, none of these domains is absolutely required for its function.
|
Identification of an additional, essential functional domain within
the proline-rich domain of SLP-76.
The panel of mutants tested
above did not include extensive mutation of the central, proline-rich
domain of SLP-76 (with the exception of the Gads-binding site
deletion). We considered the possibility that an important functional
domain of SLP-76 might be found within this large proline-rich region.
To test this possibility, we arbitrarily defined four subdomains (P-I
through P-IV), which encompass the entire proline-rich domain,
exclusive of the 21 amino acid
Gads mutation. Mutants bearing
deletions of these subdomains were constructed (Fig. 1B, constructs 6 through 9) and tested for reconstitution of TCR-mediated NFAT
activation in J14. These assays revealed that the P-I region
(encompassing residues 157 to 223 of SLP-76) is essential for SLP-76
function (Fig. 3A). By contrast, P-III
and P-IV are dispensable, while P-II has an intermediate effect on
SLP-76 function. All mutants were expressed at roughly equivalent
levels (Fig. 3A, right).
|
Effect of SLP-76 domain mutations on TCR-induced signaling through
the PLC-
1/calcium and Erk pathways.
Our initial
structure-function analysis (see above) was based on transient
transfection of J14 cells, a technique that produces a high level of
expression in a small fraction of the transfected cells. To test the
functional competence of key SLP-76 mutants at physiologic levels of
expression, J14 cells were stably transfected with four mutant
constructs, chosen to individually inactivate each of the four
functional domains of SLP-76:
P-1 (missing the P-I domain). Y3F
(three tyrosine phosphorylation sites mutated to phenylalanine),
Gads (missing the Gads-binding domain), and SH2mut
(bearing an inactivating mutation in the SH2 domain). Multiple stably
transfected clones were chosen that expressed surface TCR and a level
of SLP-76 roughly equivalent to those of wild-type Jurkat cells and the
previously described, wild-type reconstituted cell line J14-76-11 (data
not shown).
1/IP3/calcium pathway. To this
end, we used PMA to constitutively activate the Ras pathway in a
SLP-76-independent manner (64), enabling us to
specifically measure TCR-mediated signaling through the calcium
pathway. Stimulation with anti-TCR plus PMA revealed that the
P-1, Y3F, and
Gads mutants are unable to mediate signaling
through the calcium-dependent pathway leading to NFAT activation, while
the SH2mut construct is less impaired (Fig.
4A).
These results are generally consistent
with the results obtained in transient transfections described above,
although the impairments in signaling are more severe, probably due to
lower levels of expression of the SLP-76 mutant constructs.
|
1 and Erk. J14 cells exhibit significantly
reduced TCR-induced tyrosine phosphorylation of PLC-
1 compared to
SLP-76-reconstituted cells (64). Likewise, TCR-induced
tyrosine phosphorylation of PLC-
1 was reduced in
P-1-, Y3F-,
Gads- and SH2mut-reconstituted J14 cells compared to
wild-type SLP-76-reconstituted cells (Fig. 4B). However, no
reproducible differences could be observed between the different
mutants. To rule out a general effect of the mutants on TCR-induced
tyrosine phosphorylation, we examined TCR-induced tyrosine
phosphorylation of Vav, an event that we previously showed to be
independent of SLP-76 (64). As expected, we found no
difference in TCR-induced tyrosine phosphorylation of Vav in the
wild-type- or mutant-reconstituted cells (Fig. 4C). Thus, SLP-76 is
specifically required to mediate optimal TCR-induced tyrosine
phosphorylation of PLC-
1, and all four of the tested domains appear
to be required for this function. Since the overall tyrosine
phosphorylation of PLC-
1 does not always correlate with its
activation (9, 28, 45), we measured TCR-induced inositol phosphate production, a direct measure of PLC-
1 activity and a
prerequisite for TCR-induced calcium flux. Inositol phosphate production was impaired in
P-1-, Y3F-, and
Gads-reconstituted J14
cells relative to SH2mut and wild-type-reconstituted cells
(Fig. 4D). Likewise, TCR-mediated phosphorylation of Erk1 and Erk2 was
substantially reduced in
P-1-, Y3F-, and
Gads-reconstituted J14
cells relative to wild-type SLP-76, while
SH2mut-reconstituted cells exhibited Erk activation similar
to the wild-type level (Fig. 4E). We conclude that the N-terminal
tyrosine phosphorylation sites of SLP-76, the P-1, domain and the
Gads-binding domain are required for activation of PLC-
1 and Erk,
two of the events that are critical for NFAT activation. By contrast,
the SH2 domain is required for optimal tyrosine phosphorylation of
PLC-
1 but is not essential for its activation or for the downstream
responses to TCR stimulation that we have measured.
Effect of the P-I domain deletion on SLP-76-mediated
protein-protein interactions.
Of the domains that we have
identified as critical for SLP-76 function, the P-I domain is newly
defined. We sought to establish whether the P-I domain plays primarily
a structural role, enabling proper function of the other domains of
SLP-76, or whether it directly mediates protein-protein interactions.
To address this question, we examined the function of other SLP-76
domains within the context of the
P-1 mutant. Flag-tagged SLP-76 was
immunoprecipitated from the stable transfectants described above,
before or after stimulation of the TCR. An antiphosphotyrosine blot of
the immunoprecipitated proteins demonstrated that the
P-1 mutant is
inducibly tyrosine phosphorylated following TCR stimulation, as are the
wild-type,
Gads, and SH2mut proteins (Fig.
5). Thus, these mutations do not grossly
disrupt the overall conformation of SLP-76 or its ability to interact normally with TCR-activated tyrosine kinases. Likewise, the
constitutive interaction of SLP-76 with Gads is not disrupted by the
P-1, Y3F, or SH2mut mutation (Fig. 5), again suggesting
that these mutations do not grossly disrupt the overall structure of
SLP-76.
|
1.
Interestingly, the SH3 domains of the tyrosine kinases Lck and Itk have
been demonstrated to interact with sequences within the P-I domain
(3, 44). The SH3 domain of Lck binds to a proline-rich
motif encompassing amino acids 185 to 194 of SLP-76. Likewise, the SH3
domain of Itk can bind to two proline rich motifs found in residues 184 to 195 and 196 to 208 of SLP-76. We were intrigued by these findings,
since both Lck and Itk are required for optimal TCR-induced calcium
flux (28, 45, 51). However, two preliminary experiments
suggested to us that these proteins are not the main effectors by which
the P-I domain influences PLC-
1 activation. First, a deletion of
residues 181 to 203 within the P-I domain, which removes the
Lck-binding motif and removes all but one of the prolines in the
Itk-binding motifs, did not impair SLP-76 reconstitution of NFAT
activation in J14 cells (data not shown). Second, in carefully
controlled experiments, using Lck-deficient J.CaM1 cells as a negative
control, we have been unable to observe coimmunoprecipitation of either
Lck or Itk with SLP-76 (data not shown). We therefore conclude that
these kinases are not likely to be the main effectors of the SLP-76 P-1 domain.
Basal and inducible interaction of SLP-76 with PLC-
1.
We
next considered the possibility that the P-I domain may bind to the SH3
domain of PLC-
1. While some published data is suggestive of an
association between SLP-76 and PLC-
1 (24, 55), it has
not been conclusively demonstrated. We used an anti-Flag antibody to
immunoprecipitate SLP-76-associated proteins from J14-76-11 (J14,
stably reconstituted with Flag-tagged, wild-type SLP-76) and probed the
immunoprecipitates for PLC-
1. We found an inducible association
between SLP-76 and PLC-
1, which was as striking as the
well-established, inducible association between SLP-76 and Nck (Fig.
6A, lanes 1 and 2). To control for
nonspecific adsorption of proteins to the anti-Flag beads, we performed
an anti-Flag immunoprecipitation from Jurkat cells, which express untagged SLP-76. In this case, we did not observe significant PLC-
1
in the immunoprecipitates (Fig. 6A, lane 3).
|
1 association, we
immunoprecipitated Flag-tagged SLP-76 at various time points following
TCR stimulation and probed the immunoprecipitates for PLC-
1. This
experiment revealed a low but detectable association of SLP-76 with
PLC-
1 prior to stimulation and an inducible association that peaked
at 1 min and returned to basal levels by 10 min poststimulation (Fig.
6B, top gel). By contrast, probing with anti-Flag and anti-Gads revealed equal amounts of SLP-76 and equal association with Gads at
each time point (Fig. 6B, middle gels). Notably, the time course of
TCR-induced SLP-76-PLC-
1 association parallels the time course of
TCR-induced LAT tyrosine phosphorylation (49, 67), whereas SLP-76 tyrosine phosphorylation remains constant for up to 30 min
poststimulation (31). Indeed, reprobing the region of the blot corresponding to SLP-76 with antiphosphotyrosine revealed that
TCR-induced tyrosine phosphorylation of SLP-76 peaked by 30 s and
remained relatively constant throughout the course of the stimulation
(Fig. 6B, bottom gel). This different time course suggests that the
inducible association of SLP-76 with PLC-
1 may be independent of
tyrosine phosphorylation of SLP-76; rather, it may reflect the
association of both SLP-76 and PLC-
1 with LAT.
To test the role of SLP-76 functional domains in mediating its
association with PLC-
1, we reprobed the anti-Flag immunoprecipitates from Fig. 5 with anti-PLC-
1 (Fig. 6C). We found that the
Gads-binding domain is required for the inducible association of SLP-76
with PLC-
1, while the P-1 deletion primarily reduces the basal
association. In addition, a corresponding reduction the inducible
association is seen in the
P-1 mutant, suggesting that the basal
association of SLP-76 with PLC-
1 contributes to stabilization of the
inducible interaction. The Y3F mutation did not affect association with PLC-
1, confirming that the phosphorylated tyrosine residues in SLP-76 do not play a role in this interaction. Likewise, the SH2 mutation did not reproducibly affect the association of SLP-76 with
PLC-
1. From these data and from the above time course, we conclude
that the inducible interaction of SLP-76 with PLC-
1 is likely
indirect and depends on the inducible binding of both Gads and PLC-
1
to LAT. By contrast, our data suggest that the basal association may be
mediated by a constitutive interaction between the proline-rich P-I
domain of SLP-76 and the SH3 domain of PLC-
1.
Direct interaction of the PLC-
1 SH3 domain with SLP-76, mediated
by the P-1 domain of SLP-76.
To further test our hypothesis that
the SH3 domain of PLC-
1 associates with the P-I domain of SLP-76, we
examined the ability of the PLC-
1 SH3 domain to bind SLP-76 in
vitro. A GST-PLC-
1 SH3 fusion protein specifically bound to SLP-76.
By contrast, SLP-76 did not bind to GST alone, nor did it bind to a
control GST fusion protein containing the second SH3 domain of human
Nck (Fig. 7A). These results demonstrate
that the PLC-
1 SH3 can bind to SLP-76. A larger fusion protein,
encompassing the two SH2 domains and the SH3 domain of PLC-
1
(SH223), did not show increased binding to SLP-76 relative to the SH3
domain alone, nor was the interaction affected by anti-TCR stimulation
(Fig. 7B). This result provides further confirmation that the PLC-
1
SH2 domains do not interact with the sites on SLP-76 that are tyrosine
phosphorylated upon TCR stimulation in vivo. To better define the
domains of SLP-76 that interact with PLC-
1, we tested the in vitro
interaction of the PLC-
1 fusion proteins with mutant forms of SLP-76
(Fig. 7C). Our results show that the P-I domain is the only domain
required for the interaction of SLP-76 with the PLC-
1 SH3 domain
(Fig. 7C, top left) and with the SH223 construct (top right). Taken together, our results demonstrate that the SH2 domains of PLC-
1 do
not significantly bind to the in vivo-phosphorylated tyrosine phosphorylation sites on SLP-76, whereas the SH3 domain of PLC-
1 binds to a site within the P-I domain of SLP-76. This interaction is
responsible for the basal association of SLP-76 with PLC-
1 and is
likely to be the basis for the functional importance of this domain.
|
| |
DISCUSSION |
|---|
|
|
|---|
SLP-76 plays an essential role in coupling ITAM-containing
receptors (including the TCR, the high-affinity IgE receptor, and the
platelet collagen receptor) to tyrosine phosphorylation and activation
of PLC-
1 and PLC-
2 and to subsequent calcium flux (5, 17,
37, 64). Nonetheless, the mechanisms by which SLP-76 influences
PLC-
tyrosine phosphorylation and activation have not been
elucidated. In this study, we used mutational analysis to identify the
domains of SLP-76 required for PLC-
1 activation, taking advantage of
the SLP-76-deficient J14 cells as an ideal genetic background for
structure-function analysis of SLP-76. Our studies resulted in the
identification of a previously unrecognized, essential functional
domain within the proline-rich domain of SLP-76. Further, we have
identified an association between this domain and the SH3 domain of
PLC-
1.
Using the NFAT activation assays as a biologically relevant readout for
SLP-76 function, we initially used transient transfection assays to
test the requirement for previously defined functional domains of
SLP-76: the N-terminal tyrosine phosphorylation sites, the Gads-binding
domain, and the SH2 domain (14, 33). These experiments
confirmed that each of these domains contributes to SLP-76 function.
Nevertheless, we were surprised to find that none of the above domains
is absolutely required for TCR-mediated NFAT activation. Assuming that
SLP-76 must interact with one or more essential effector proteins in
order to mediate activation of PLC-
1 and NFAT, how can one explain
that individual mutation of each of the known protein-protein
interaction domains of SLP-76 fails to completely abrogate SLP-76
function? One possibility is that the best-characterized
SLP-76-interacting proteins, including Vav, Nck, Gads, and
SLAP-130/Fyb, which associate with the previously defined functional
domains of SLP-76, may be dispensable for SLP-76-mediated signaling
events leading to NFAT activation. Another possibility is that SLP-76
may form a multivalent interaction with a critical effector protein,
and that this interaction is weakened but not completely disrupted by
individual mutation of each interaction site. However, we considered
the alternate possibility, that an important effector of SLP-76 may
bind to a site not encompassed by the above mutations.
These considerations led us to examine other regions of SLP-76,
revealing a requirement for residues 157 to 223 to mediate TCR-induced
activation of Erk, PLC-
1, and NFAT. We have designated this region
the P-I domain. Deletion of the P-I domain does not grossly disrupt the
overall conformation of SLP-76, as the P-I deletion protein is
inducibly tyrosine phosphorylated in response to TCR stimulation, binds
to Gads, and binds inducibly to PLC-
1. We therefore concluded that
the P-I domain is likely to mediate a functionally important
interaction with an effector protein and that this interaction is
required for optimal activation of PLC-
1.
The 67-amino-acid P-I domain is extremely proline rich, containing a
total of 20 proline residues. Not surprisingly, it has been found to
associate with a number of SH3 domains, including the SH3 domains of
Lck (44), Itk (3), and PLC-
1 (this study). Several considerations led us to conclude that neither Lck nor Itk is
the physiologically relevant effector of the SLP-76 P-I domain. In
carefully controlled immunoprecipitation experiments, we detected
association of full-length SLP-76 with PLC-
1 but not with Lck or
Itk. Indeed, Bunnell et al. (3) have demonstrated only a modest interaction between full-length SLP-76 and Itk, using
proteins overexpressed in a baculoviral system. In the context of total
cellular proteins, this modest interaction may be competed off by
other, more physiologic interactions. In addition, a deletion of 22 amino acids within the P-I domain (181 to 203), which removes the
putative binding sites of Lck and Itk, does not impair SLP-76 function
(data not shown). Finally, studies from other laboratories suggest that
the SH3 domains of Lck and Tec family kinases do not play essential
roles in the activation of PLC-
and calcium flux, whereas the SH3
domain of PLC-
1 is required. Lck-deficient J.CaM1.6 cells,
reconstituted with SH3-mutated Lck, show normal activation of PLC-
1
and normal calcium flux (10). Likewise, overexpression of
an SH3-deletion mutant of the Tec family kinase Btk (the B-cell
homologue of Itk) leads to augmented BCR-induced calcium flux
(46), a result that would not be expected if the SH3
domain of Tec family kinases played a major role in mediating activation of PLC-
. In contrast, the SH3 domain of PLC-
1 is required for optimal inositol phosphate production and NFAT activation following stimulation of the BCR in B cells (9). These
considerations suggest that while both Lck and Itk are required for
optimal TCR-induced calcium flux (28, 45, 51), their
effect on calcium flux is not mediated by binding of their SH3 domains
to the P-1 domain of SLP-76. Rather, the physiologically important
effector of the P-1 domain appears to be PLC-
1.
The association between SLP-76 and PLC-
1 has two components: a basal
component and a TCR-inducible component. These components are largely
independent of each other and are mediated by different domains of
SLP-76. The basal component depends on the P-1 domain of SLP-76, which
associates with the SH3 domain of PLC-
1. Notably, the
P-1 mutant
still binds inducibly to PLC-
1, indicating that a different domain
of SLP-76 mediates the inducible association. One might think that the
inducible component reflects binding of the SH2 domains of PLC-
1 to
the tyrosine phosphorylation sites of SLP-76. However, we found no
evidence to support this possibility. We observed no in vitro binding
of the SH2 domains of PLC-
1 to tyrosine phosphorylated SLP-76 from
TCR-stimulated cells. Furthermore, the inducible component was not
affected by mutation of the SLP-76 tyrosine phosphorylation sites.
Rather, the inducible association depended on the Gads-binding domain
of SLP-76, which mediates recruitment of SLP-76 to LAT, and followed a
time course that paralleled the time course of LAT tyrosine
phosphorylation. We conclude that the inducible association of SLP-76
with PLC-
1 is indirect and is due to recruitment of both proteins to
tyrosine-phosphorylated LAT. Thus, a web of interactions connects
PLC-
1 to the SLP-76, LAT, and Gads adapters (Fig.
8). Both PLC-
1 and Gads bind inducibly to LAT via their SH2 domains (1, 29, 50). Concomitantly, the SH3 domain of Gads binds constitutively to SLP-76 (1, 26, 29), which, in turn, binds constitutively to the SH3 domain of
PLC-
1 (this study).
|
How does this web of interactions bring about the activation of
PLC-
1? First, the recruitment of PLC-
1 to LAT appears to be
essential for its TCR-induced tyrosine phosphorylation and activation.
Indeed, mutation of the single PLC-
1 SH2 domain consensus binding
site in LAT is sufficient to abrogate TCR-induced tyrosine phosphorylation of PLC-
1 (68). SLP-76 is not required
for the TCR-induced association of PLC-
1 with LAT (64);
furthermore, LAT is an integral membrane protein, suggesting that the
PLC-
1-LAT interaction is probably sufficient to localize PLC-
1
to the membrane. Nonetheless, SLP-76 is required to fully activate the
membrane-localized PLC-
1 (64). We have found that the
P-I domain of SLP-76 associates with the SH3 domain of PLC-
1 and is
required to mediate activation of PLC-
1. Based on this finding, we
suggest that this interaction is likely to play a role in the
regulation of PLC-
1 by SLP-76.
Examination of the interactions depicted in Fig. 8 suggests a number of
mechanisms by which SLP-76 could contribute to the activation of
PLC-
1. One possibility is that SLP-76 stabilizes the recruitment of
PLC-
1 to LAT. SH2- and SH3-mediated interactions are generally of
relatively low affinity, such that a single interaction between the
N-terminal SH2 domain of PLC-
1 and LAT might not be stable enough to
keep PLC-
1 at the membrane. However, the direct interaction of each
of the proteins in the complex with two other proteins could serve to
stabilize the complex as a whole, thereby stabilizing the recruitment
of PLC-
1 to the membrane. In support of this hypothesis, Zhang et
al. have found that mutation of the Gads-binding sites on LAT
significantly reduces the binding of PLC-
1 to LAT (68).
Nonetheless, we do not believe that the role of SLP-76 is limited to
stabilizing the recruitment of PLC-
1 to the membrane. Experiments in
B cells show that membrane-targeted PLC-
is not efficiently
activated by BCR stimulation in the absence of other interactions
mediated by the PLC-
SH domains (9, 23). Thus, we
believe that the interaction of SLP-76 with the SH3 domain of PLC-
1
exerts an important regulatory influence on PLC-
1 once it is at the
membrane. In particular, the direct binding of the N-terminal SH2 and
SH3 domains of PLC-
1 to LAT and SLP-76, respectively, may
conformationally constrain the SH region of PLC-
1. The result of
this conformational change may be a relief of the autoinhibitory
function exerted by the SH domains of PLC-
1 (19, 20)
and/or a stretching of the intervening region between the SH2 and SH3
domains. Since two of the tyrosine phosphorylation sites of PLC-
1
are located within this intervening region, a SLP-76-induced
conformational change in the SH region of PLC-
1 may result in better
accessibility of these tyrosines to phosphorylation.
The above, speculative model accounts for the role of the P-I and
Gads-binding domains of SLP-76 in mediating optimal activation of
PLC-
1. In addition, our data demonstrate that the N-terminal tyrosine phosphorylation sites of SLP-76 are required for PLC-
1 activation. Recent studies suggest that these phosphorylation sites may
bind to Tec family tyrosine kinases Itk and/or Rlk (3, 47,
52), which are required for TCR-mediated activation of PLC-
1
(28, 45). It is possible that SLP-76 may not only affect the conformation of PLC-
1 and its accessibility to tyrosine kinases but also recruit the appropriate tyrosine kinase required for phosphorylation of a subset of the tyrosine phosphorylation sites of
PLC-
1, leading to its activation.
This study identifies SLP-76 as a physiologic ligand for the SH3 domain
of PLC-
1 and provides evidence that this interaction plays an
essential role in SLP-76-mediated activation of PLC-
1. BCR-mediated
activation of PLC-
1 and -
2 occurs by an analogous but not
identical mechanism, due to the different adapter proteins expressed in
the two cell types. TCR-mediated activation of PLC-
1 requires SLP-76
and LAT (15, 64), whereas BCR-mediated PLC-
1 activation
requires BLNK (22), an adapter which bears overall structural similarity to SLP-76 but only 33% homology (16,
58). No analog of LAT has been identified in B cells, where BLNK
is thought to fulfill the function of both adapters (16,
59). In keeping with this dual role of BLNK, the SH2 domains of
PLC-
1, which associate with tyrosine-phosphorylated LAT in T cells,
bind to tyrosine phosphorylated BLNK in B cells (9, 23).
Nonetheless, this interaction does not rule out an additional
interaction between the SH3 domain of PLC-
1 and the proline-rich
domain of BLNK, which may be required for activation of PLC-
1 in
this system. This possibility awaits further investigation.
It is important to note that our analysis is limited to an investigation of the SLP-76 domains required for NFAT activation. SLP-76 is likely to participate in additional signaling pathways, such as those that lead to TCR-induced actin polymerization (55) or the activation of HPK1 (27). The requirements for SLP-76 domains and effector proteins for signaling through these pathways may differ and will require further analysis.
| |
ACKNOWLEDGMENTS |
|---|
We thank Gary Koretzky, Bruce Mayer, Yossi Schlessinger, C. Jane McGlade, and Graham Carpenter for reagents provided. We thank the members of the Weiss lab for their support and for helpful discussions.
This work was supported in part by the Howard Hughes Medical Institute and by grant CA72531 from the National Cancer Institute.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medicine, Department of Microbiology and Immunology, and Howard Hughes Medical Institute, U426, Box 0795, University of California, San Francisco, 533 Parnassus Ave., San Francisco, CA 94143-0795. Phone: (415) 476-1291. Fax: (415) 502-5081. E-mail: aweiss{at}medicine.ucsf.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Asada, H.,
N. Ishii,
Y. Sasaki,
K. Endo,
H. Kasai,
N. Tanaka,
T. Takeshita,
S. Tsuchiya,
T. Konno, and K. Sugamura.
1999.
Grf40, a novel Grb2 family member, is involved in T cell signaling through interactions with SLP-76 and LAT.
J. Exp. Med.
189:1383-1390 |
| 2. | Bourette, R. P., S. Arnaud, G. M. Myles, J.-P. Blanchet, and L. R. Rohrschneider. 1998. Mona, a novel hematopoietic-specific adaptor interacting with the macrophage colony-stimulating factor receptor, is implicated in monocyte/macrophage development. EMBO J. 17:7273-7281[CrossRef][Medline]. |
| 3. |
Bunnell, S. C.,
M. Diehn,
M. B. Yaffe,
P. R. Findell,
L. C. Cantley, and L. J. Berg.
2000.
Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade.
J. Biol. Chem.
275:2219-2230 |
| 4. |
Carpenter, G., and Q.-S. Ji.
1999.
Phospholipase C- as a signal transducing element.
Exp. Cell Res.
253:15-24[CrossRef][Medline].
|
| 5. | Clements, J. L., J. R. Lee, B. Gross, B. Yang, J. D. Olson, A. Sandra, S. P. Watson, S. R. Lentz, and G. A. Koretzky. 1999. Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. J. Clin. Investig. 103:19-25[Medline]. |
| 6. |
Clements, J. L.,
S. E. Ross-Barta,
L. T. Tygrett,
T. J. Waldschmidt, and G. A. Koretzky.
1998.
SLP-76 expression is restricted to hemopoietic cells of monocyte, granulocyte and T lymphocyte lineage and is regulated during T cell maturation and activation.
J. Immunol.
161:3880-3889 |
| 7. |
Clements, J. L.,
B. Yang,
S. E. Ross-Barta,
S. L. Eliason,
R. F. Hrstka,
R. A. Williamson, and G. A. Koretzky.
1998.
Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development.
Science
281:416-419 |
| 8. |
da Silva, A. J.,
Z. Li,
C. De Vera,
E. Canto,
P. Findell, and C. E. Rudd.
1997.
Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-containing leukocyte protein 76 and modulates interleukin 2 production.
Proc. Natl. Acad. Sci. USA
94:7493-7498 |
| 9. |
DeBell, K. E.,
B. A. Stoica,
M.-C. Veri,
A. Di Baldassarre,
S. Miscia,
L. J. Graham,
B. L. Rellahan,
M. Ishiai,
T. Kurosaki, and E. Bonvini.
1999.
Functional independence and interdependence of the src homology domains of phospholipase C- 1 in B-cell receptor signal transduction.
Mol. Cell. Biol.
19:7388-7398 |
| 10. |
Denny, M. F.,
H. C. Kaufman,
A. C. Chan, and D. B. Straus.
1999.
The Lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling.
J. Biol. Chem.
274:5146-5152 |
| 11. |
Ebinu, J. O.,
S. L. Stang,
C. Teixeira,
D. A. Bottorff,
J. Hooton,
P. M. Blumberg,
M. Barry,
C. Bleakley,
H. L. Ostergaard, and J. C. Stone.
2000.
RasGRP links T-cell receptor signaling to Ras.
Blood
95:3199-3203 |
| 12. |
Ellis, J. H.,
C. Ashman,
M. N. Burden,
K. E. Kilpatrick,
M. A. Morse, and P. A. Hamblin.
2000.
GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28.
J. Immunol.
164:5805-5814 |
| 13. |
Fang, N., and G. A. Koretzky.
1999.
SLP-76 and Vav function in separate, but overlapping pathways to augment interleukin-2 promoter activity.
J. Biol. Chem.
274:16206-16212 |
| 14. | Fang, N., D. G. Motto, S. E. Ross, and G. A. Koretzky. 1996. Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity. J. Immunol. 157:3769-3773[Abstract]. |
| 15. |
Finco, T. S.,
T. Kadlecek,
W. Zhang,
L. E. Samelson, and A. Weiss.
1998.
LAT is required for TCR-mediated activation of PLC 1 and the Ras pathway.
Immunity
9:617-626[CrossRef][Medline].
|
| 16. | Fu, C., C. W. Turck, T. Kurosaki, and A. C. Chan. 1998. BLNK: a central linker protein in B cell activation. Immunity 9:93-103[CrossRef][Medline]. |
| 17. |
Gross, B. S.,
J. R. Lee,
J. L. Clements,
M. Turner,
V. L. J. Tybulewicz,
P. R. Findell,
G. A. Koretzky, and S. P. Watson.
1999.
Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets.
J. Biol. Chem.
274:5963-5971 |
| 18. |
Hashimoto, A.,
H. Okada,
A. Jiang,
M. Kurosaki,
S. Greenberg,
E. A. Clark, and T. Kurosaki.
1998.
Involvement of guanosine triphosphatases and phospholipaseC- 2 in extracellular signal-regulated kinase, c-jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor.
J. Exp. Med.
188:1287-1295 |
| 19. |
Homma, Y., and T. Takenawa.
1992.
Inhibitory effect of src homology (SH) 2/SH3 fragments of phospholipase C-gamma on the catalytic activity of phospholipase C isoforms. Identification of a novel phospholipase C inhibitor region.
J. Biol. Chem.
267:21844-21849 |
| 20. |
Horstman, D. A.,
A. Chattopadhyay, and G. Carpenter.
1999.
The influence of deletion mutations on phospholipase C- 1 activity.
Arch. Biochem. Biophys.
361:149-155[CrossRef][Medline].
|
| 21. |
Imboden, J. B., and J. D. Stobo.
1985.
Transmembrane signaling by the T cell antigen receptor.
J. Exp. Med.
161:446-456 |
| 22. |
Ishiai, M.,
M. Kurosaki,
R. Pappu,
K. Okawa,
I. Ronko,
C. Fu,
M. Shibata,
A. Iwamatsu,
A. C. Chan, and T. Kurosaki.
1999.
BLNK required for coupling Syk to PLC 2 and Rac1-JNK in B cells.
Immunity
10:117-125[CrossRef][Medline].
|
| 23. |
Ishiai, M.,
H. Sugawara,
M. Kurosaki, and T. Kurosaki.
1999.
Cutting edge: association of phospholipase C- 2 src homology 2 domains with BLNK is critical for B cell antigen receptor signaling.
J. Immunol.
163:1746-1749 |
| 24. |
Jackman, J. K.,
D. G. Motto,
Q. Sun,
M. Tanemoto,
C. W. Turck,
G. A. Peltz,
G. A. Koretzky, and P. R. Findell.
1995.
Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated with Grb2 in T cells.
J. Biol. Chem.
270:7029-7032 |
| 25. |
Kim, H. K.,
J. W. Kim,
A. Zilberstein,
B. Margolis,
J. G. Kim,
J. Schlessinger, and S. G. Rhee.
1991.
PDGF stimulation of inositol phospholipid hydrolysis requires PLC- 1 phosphorylation on tyrosine residues 783 and 1254.
Cell
65:435-441[CrossRef][Medline].
|
| 26. |
Law, C.-L.,
M. K. Ewings,
P. M. Chaudhary,
S. A. Solow,
T. J. Yun,
A. J. Marshall,
L. Hood, and E. A. Clark.
1999.
GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation.
J. Exp. Med.
189:1243-1253 |
| 27. | Liou, J., F. Kiefer, A. Dang, A. Hashimoto, M. H. Cobb, T. Kurosaki, and A. Weiss. 2000. HPK1 is activated by lymphocyte antigen receptors and negatively regulates AP-1. Immunity 12:399-408[CrossRef][Medline]. |
| 28. |
Liu, K.-Q.,
S. C. Bunnell,
C. B. Gurniak, and L. J. Berg.
1998.
T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells.
J. Exp. Med.
187:1721-1727 |
| 29. | Liu, S. K., N. Fang, G. A. Koretzky, and C. J. McGlade. 1999. The hematopoietic-specific adaptor protein Gads functions in T-cell signaling via interactions with the SLP-76 and LAT adaptors. Curr. Biol. 9:67-75[CrossRef][Medline]. |
| 30. |
Mizushima, S., and S. Nagata.
1990.
pEF-BOS, a powerful mammalian expression vector
Nucleic Acids Res.
18:5322 |
| 31. |
Motto, D. G.,
S. E. Ross,
J. Wu,
L. R. Hendricks-Taylor, and G. A. Koretzky.
1996.
Implication of the GRB2-associated phosphoprotein SLP-76 in T cell receptor-mediated interleukin 2 production.
J. Exp. Med.
183:1937-1943 |
| 32. |
Musci, M. A.,
L. R. Hendricks-Taylor,
D. G. Motto,
M. Paskind,
J. Kamens,
C. W. Turck, and G. A. Koretzky.
1997.
Molecular cloning of SLAP-130, an SLP-76-associated substrate of the T cell antigen receptor-stimulated protein tyrosine kinases.
J. Biol. Chem.
272:11674-11677 |
| 33. | Musci, M. A., D. G. Motto, S. E. Ross, N. Fang, and G. A. Koretzky. 1997. Three domains of SLP-76 are required for its optimal function in a T cell line. J. Immunol. 159:1639-1647[Abstract]. |
| 34. |
Pawson, T., and J. D. Scott.
1997.
Signaling through scaffold, anchoring, and adaptor proteins.
Science
278:2075-2080 |
| 35. | Peterson, E. J., J. L. Clements, Z. K. Ballas, and G. A. Koretzky. 1999. NK cytokine secretion and cytotoxicity occur independently of the SLP-76 adaptor protein. Eur. J. Immunol. 29:2223-2232[CrossRef][Medline]. |
| 36. | Pivniouk, V., E. Tsitsikov, P. Swinton, G. Rathbun, F. W. Alt, and R. S. Geha. 1998. Impaired viability and profound block in thymocyte development in mice lacking the adaptor protein SLP-76. Cell 94:229-238[CrossRef][Medline]. |
| 37. | Pivniouk, V. I., T. R. Martin, J. M. Lu-Kuo, H. R. Katz, H. C. Oettgen, and R. S. Geha. 1999. SLP-76 deficiency impairs signaling via the high-affinity IgE receptor in mast cells. J. Clin. Investig. 103:1737-1743[Medline]. |
| 38. | Qian, D., and A. Weiss. 1997. T cell antigen receptor signal transduction. Curr. Opin. Cell Biol. 9:205-212[CrossRef][Medline]. |
| 39. | Qiu, M., S. Hua, M. Agrawal, G. Li, J. Cai, E. Chan, H. Zhou, Y. Luo, and M. Liu. 1998. Molecular cloning and expression of human Grap-2, a novel leukocyte-specific SH2- and SH3-containing adaptor-like protein that binds to Gab-1. Biochem. Biophys. Res. Commun. 253:443-447[CrossRef][Medline]. |
| 40. | Raab, M., A. J. da Silva, P. R. Findell, and C. E. Rudd. 1997. Regulation of Vav-SLP-76 binding by ZAP-76 and its relevance to TCR/CD3 induction of interleukin-2. Immunity 6:155-164[CrossRef][Medline]. |
| 41. | Rao, A., C. Luo, and P. G. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707-747[CrossRef][Medline]. |
| 42. |
Rhee, S. G., and Y. S. Bae.
1997.
Regulation of phosphoinositide-specific phospholipase C isozymes.
J. Biol. Chem.
272:15043-15048 |
| 43. |
Robinson, A.,
J. Gibbins,
B. Rodriguez-Linares,
P. M. Finan,
L. Wilson,
S. Kellie,
P. Findell, and S. P. Watson.
1996.
Characterization of Grb2-binding proteins in human platelets activated by Fc RIIA cross-linking.
Blood
88:522-530 |
| 44. |
Sanzenbacher, R.,
D. Kabelitz, and O. Janssen.
1999.
SLP-76 binding to p56lck: a role for SLP-76 in CD4-induced desensitization of the TCR/CD3 signaling complex.
J. Immunol.
163:3143-3152 |
| 45. |
Schaeffer, E. M.,
J. Debnath,
G. Yap,
D. McVicar,
X. C. Liao,
D. R. Littman,
A. Sher,
H. E. Varmus,
M. J. Lenardo, and P. L. Schwartzberg.
1999.
Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity.
Science
284:638-641 |
| 46. | Scharenberg, A. M., O. El-Hillal, D. A. Fruman, L. O. Beitz, Z. Li, S. Lin, I. Gout, L. C. Cantley, D. J. Rawlings, and J.-P. Kinet. 1998. Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 17:1961-1972[CrossRef][Medline]. |
| 47. |
Schneider, H.,
B. Guerette,
C. Guntermann, and C. E. Rudd.
2000.
Resting lymphocyte kinase (Rlk/Txk) targets lymphoid adaptor SLP-76 in the cooperative activation of interleukin-2 transcription in T-cells.
J. Biol. Chem.
275:3835-3840 |
| 48. |
Sekiya, F.,
Y. S. Bae, and S. G. Rhee.
1999.
Regulation of phospholipase C isozymes: activation of phospholipase C- in the absence of tyrosine phosphorylation.
Chem. Phys. Lipids
98:3-11[CrossRef][Medline].
|
| 49. |
Sieh, M.,
A. Batzer,
J. Schlessinger, and A. Weiss.
1994.
GRB2 and phospholipase C- 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation.
Mol. Cell. Biol.
14:4435-4442 |
| 50. |
Stoica, B.,
K. E. DeBell,
L. Graham,
B. L. Rellahan,
M. A. Alava,
J. Laborda, and E. Bonvini.
1998.
The amino-terminal src homology 2 domain of phospholipase C 1 is essential for TCR-induced tyrosine phosphorylation of phospholipase C 1.
J. Immunol.
160:1059-1066 |
| 51. | Straus, D. B., and A. Weiss. 1992. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 70:585-593[CrossRef][Medline]. |
| 52. | Su, Y.-W., Y. Zhang, J. Schweikert, G. A. Koretzky, M. Reth, and J. Wienands. 1999. Interaction of SLP adaptors with the SH2 domain of Tec family kinases. Eur. J. Immunol. 29:3702-3711[CrossRef][Medline]. |
| 53. |
Tuosto, L.,
F. Michel, and O. Acuto.
1996.
p95vav associates with tyrosine phosphorylated SLP-76 in antigen-stimulated T cells.
J. Exp. Med.
184:1161-1166 |
| 54. |
Wardenburg, J. B.,
C. Fu,
J. K. Jackman,
H. Flotow,
S. E. Wilkinson,
D. H. Williams,
R. Johnson,
G. Kong,
A. C. Chan, and P. R. Findell.
1996.
Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function.
J. Biol. Chem.
271:19641-19644 |
| 55. | Wardenburg, J. B., R. Pappu, J.-Y. Bu, B. Mayer, J. Chernoff, D. Straus, and A. C. Chan. 1998. Regulation of PAK activation and the T cell cytoskeleton by the linker protein SLP-76. Immunity 9:607-616[CrossRef][Medline]. |
| 56. |
Weber, J. R.,
S. Orstavik,
K. M. Torgersen,
N. C. Danbolt,
S. F. Berg,
J. C. Ryan,
T. Kjetil,
J. B. Imboden, and J. T. Vaage.
1998.
Molecular cloning of the cDNA encoding pp36, a tyrosine-phosphorylated adaptor protein selectively expressed by T cells and natural killer cells.
J. Exp. Med.
187:1157-1161 |
| 57. |
Weiss, A., and J. D. Stobo.
1984.
Requirement for the coexpression of t3 and the T cell antigen receptor on a malignant human T cell line.
J. Exp. Med.
160:1284-1299 |
| 58. |
Wienands, J.,
J. Schweikert,
B. Wollscheid,
H. Jumaa,
P. J. Nielsen, and M. Reth.
1998.
SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation.
J. Exp. Med.
188:791-795 |
| 59. |
Wong, J.,
M. Ishiai,
T. Kurosaki, and A. C. Chan.
2000.
Functional complementation of BLNK by SLP-76 and LAT linker proteins.
J. Biol. Chem.
275:33116-33122 |
| 60. |
Woodrow, M.,
N. A. Clipstone, and D. Cantrell.
1993.
p21ras and calcineurin synergize to regulate the nuclear factor of activated T cells.
J. Exp. Med.
178:1517-1522 |
| 61. | Wu, J., S. Katzav, and A. Weiss. 1995. A functional T-cell receptor signaling pathway is required for p95Vav activity. Mol. Cell. Biol. 15:4337-4346[Abstract]. |
| 62. | Wu, J., D. G. Motto, G. A. Koretzky, and A. Weiss. 1996. Vav and SLP-76 interact and functionally cooperate in IL-2 gene activation. Immunity 4:593-602[CrossRef][Medline]. |
| 63. | Wunderlich, L., A. Farago, J. Downward, and L. Buday. 1999. Association of Nck with tyrosine-phosphorylated SLP-76 in activated T lymphocytes. Eur. J. Immunol. 29:1068-1075[CrossRef][Medline]. |
| 64. |
Yablonski, D.,
M. R. Kuhne,
T. Kadlecek, and A. Weiss.
1998.
Uncoupling of nonreceptor tyrosine kinases from PLC- 1 in an SLP-76-deficient T cell.
Science
281:413-416 |
| 65. | Yang, W.-C., Y. Collette, J. A. Nunes, and D. Olive. 2000. Tec kinases: a family with multiple roles in immunity. Immunity 12:373-382[CrossRef][Medline]. |
| 66. |
Zhang, W.,
B. J. Irvin,
R. P. Trible,
R. T. Abraham, and L. E. Samelson.
1999.
Functional analysis of LAT in TCR-mediated signaling pathways using a LAT-deficient Jurkat cell line.
Int. Immunol.
11:943-950 |
| 67. | Zhang, W., J. Sloan-Lancaster, J. Kitchen, R. P. Trible, and L. E. Samelson. 1998. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92:83-92[CrossRef][Medline]. |
| 68. |
Zhang, W.,
R. P. Trible,
M. Zhu,
S. K. Liu,
C. J. McGlade, and L. E. Samelson.
2000.
Association of Grb2, Gads and phospholipase C- 1 with phosphorylated LAT tyrosine residues.
J. Biol. Chem.
275:23355-23361 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»